Clinical Trial

Efficacy and Safety of VDPHL01 in Males With AGA

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated November 6, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13). The first 7 visits will be part of the placebo-controlled period. The next 3 visits will be part of the treatment extension phase. All subjects will receive active drug in the treatment extension phase.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-12-04; most recent amendment 2025-11-04.
Status change: Recruiting → Active, Not Recruiting 2025-08-26
Trial Details
NCT Number NCT06724614
Lead Sponsor Veradermics, Inc.
Conditions Androgenetic Alopecia, AGA, Male Pattern Baldness
Enrollment 480 participants
Start Date 2024-11-06
Primary Completion 2026-02 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-11-06